![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 14
2020
Bothou, C.; Beuschlein, F. und Spyroglou, A.
(2020):
Links between aldosterone excess and metabolic complications: A comprehensive review.
In: Diabetes & Metabolism, Bd. 46, Nr. 1: S. 1-7
2019
Lechner, B.; Heinrich, D.; Noelting, S.; Osswald-Kopp, A.; Rubinstein, G.; Sauerbeck, J.; Beuschlein, F. und Reincke, M.
(2019):
Update endokrine Hypertonie.
In: Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie, Bd. 69, Nr. 3: S. 173-190
2018
Crona, J.; Beuschlein, F.; Pacak, K. und Skogseid, B.
(2018):
Advances in adrenal tumors 2018.
In: Endocrine-Related Cancer, Bd. 25, Nr. 7:
R405-R420
Lechner, B.; Heinrich, D.; Noelting, S.; Osswald-Kopp, A.; Rubinstein, G.; Sauerbeck, J.; Beuschlein, F. und Reincke, M.
(2018):
Update endokrine Hypertonie.
In: Internist, Bd. 59, Nr. 11: S. 1163-1179
2017
Perez-Rivas, L. G.; Rhayem, Y.; Sabrautzki, S.; Hantel, C.; Rathkolb, B.; Hrabe de Angelis, M.; Reincke, M.; Beuschlein, F. und Spyroglou, A.
(2017):
Genetic characterization of a mouse line with primary aldosteronism.
In: Journal of Molecular Endocrinology, Bd. 58, Nr. 2: S. 67-78
Dalmazi, G. D. und Beuschlein, F.
(2017):
PRKACA Mutations in Adrenal Adenomas: Genotype/Phenotype Correlations.
In: Hormone and Metabolic Research, Bd. 49, Nr. 4: S. 301-306
Peverelli, E.; Catalano, R.; Giardino, E.; Treppiedi, D.; Morelli, V.; Ronchi, C. L.; Vaczlavik, A.; Fusco, N.; Ferrero, S.; Bertherat, J.; Beuschlein, F.; Chiodini, I.; Arosio, M.; Spada, A. und Mantovani, G.
(2017):
Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells.
In: Cancer Letters, Bd. 406: S. 54-63
2016
Tauber, Philipp; Aichinger, B.; Christ, C.; Stindl, J.; Rhayem, Y.; Beuschlein, F.; Warth, R. und Bandulik, S.
(2016):
Cellular Pathophysiology of an Adrenal Adenoma-Associated Mutant of the Plasma Membrane Ca²⁺-ATPase ATP2B3.
In: Endocrinology, Bd. 157, Nr. 6: S. 2489-2499
Åkerström, T.; Carling, T.; Beuschlein, F. und Hellman, P.
(2016):
Genetics of adrenocortical tumours.
In: Journal of internal Medicine, Bd. 280, Nr. 6: S. 540-550
Majidi, F.; Martino, S.; Haase, M.; Chortis, V; Arlt, W.; Spyroglou, A.; Beuschlein, F.; Fassnacht, M.; Kanji, A.; Habra, M. A.; Schott, M.; Haas, R. und Gattermann, N.
(2016):
Multicenter case series of primary adrenal lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 72-73
2015
Lefevre, L.; Omeiri, H.; Drougat, L.; Hantel, C.; Giraud, M.; Val, P.; Rodriguez, S.; Perlemoine, K.; Blugeon, C.; Beuschlein, F.; de Reynies, A.; Rizk-Rabin, M.; Bertherat, J. und Ragazzon, B.
(2015):
Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of beta-catenin in adrenocortical carcinoma.
In: Oncogenesis, Bd. 4
[PDF, 4MB]
2013
Reisch, N.; Rottenkolber, Marietta; Greifenstein, A.; Krone, N.; Schmidt, H.; Reincke, M.; Schwarz, H. P. und Beuschlein, F.
(2013):
Testicular adrenal rest tumors develop independently of long-term disease control: A longitudinal analysis of 50 adult men with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency.
In: Journal of Clinical Endocrinology & Metabolism, Bd. 98, Nr. 11, E1820-E1826
2012
Betz, M. J.; Hatiboglu, N.; Mauracher, B.; Hadaschik, D.; Sauter, A.; Demmelmair, Hans; Koletzko, Berthold; Beuschlein, F. und Slawik, M.
(2012):
Mc2 receptor knockdown modulates differentiation and lipid composition in adipocytes.
In: Hormone and metabolic research, Bd. 44, Nr. 9: S. 670-675
2009
Reisch, N.; Flade, L.; Scherr, M.; Rottenkolber, Marietta; Pedrosa, Gil Francisco; Bidlingmaier, M.; Wolff, H.; Schwarz, H. P.; Quinkler, M.; Beuschlein, F. und Reincke, M.
(2009):
High prevalence of reduced fecundity in men with congenital adrenal hyperplasia.
In: Journal of Clinical Endocrinology & Metabolism, Bd. 94, Nr. 5: S. 1665-1670